<DOC>
	<DOCNO>NCT02372578</DOCNO>
	<brief_summary>The purpose study assess analgesic efficacy ASP3662 relative placebo subject painful diabetic peripheral neuropathy ( PDPN ) well assess safety tolerability ASP3662 relative placebo . The analgesic effect evaluate measure percent responder , change daily worst pain score , change average daily pain score , Patient Global Impression Change ( PGIC ) Clinical Global Impression Change ( CGIC ) .</brief_summary>
	<brief_title>Study Assess Analgesic Efficacy Safety ASP3662 Subjects With Painful Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Subject BMI ≤ 40 . Subject following : 1 . Established diagnosis diabetes ( Type I II ) painful diabetic peripheral neuropathy glycosylated hemoglobin ( HgbA1c ) ≤ 9.5 % Screening Randomization . 2 . Stable diabetic drug regimen least 3 month prior Screening . 3 . At least 1 year history PDPN . 4 . Diagnosis PDPN confirm score ≥ 3 Michigan Neuropathy Screening Instrument ( MNSI ) Screening . Subject pain intensity score ( ) ≥ 4 ≤ 9 11point numeric pain rating scale ( NPRS ) Screening Visit prior Randomization . Subject agree complete pain diary complaint daily pain record prior Randomization define completion minimum 5 7 daily pain rating , 3 require last 4 day . Subject 's antidiabetic regimen anticipate stable throughout study . Subject must willing washout medication currently take his/her PDPN ( chronic occasional/as need ) remain pain medication participate study . Subject receive prior treatment pregabalin PDPN consider unresponsive intolerant . Subject try fail 3 drug treat PDPN within past 3 year . Drugs must administer therapeutic dos administer adequate period time . Subject know hypersensitivity ASP3662 , pregabalin , gabapentin acetaminophen , formulation component . Subject significant pain ( moderate ) due cause PDPN . Subject history painful peripheral neuropathy due cause diabetes . Subject low extremity amputation Subject current previous foot ulcer within past 3 month describe medical history and/or medical examination . Subject active malignancy history malignancy ( except treat nonmelanoma skin cancer ) within 5 year . Subject clinically significant abnormality clinical chemistry , hematology , urinalysis , serum creatinine Screening . Subject creatinine clearance &lt; 60 mL/min ( estimate serum creatinine , body weight , age , sex use Cockcroft Gault equation ) Screening . Subject test positive hepatitis B surface antigen ( HBsAg ) hepatitis C antibody Screening known history positive test human immunodeficiency virus ( HIV ) infection . Subject positive drug screen alcohol drug abuse Screening and/or Randomization . Subjects low dos benzodiazepine sleep legitimate prescription allow study . In addition , subject positive drug screen Randomization exclude . Subject currently use protocol specify nonpermitted medication include OTC product unable choose discontinue . Subject plan elective surgery plan study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Painful diabetic peripheral neuropathy ( PDPN )</keyword>
	<keyword>ASP3662</keyword>
</DOC>